MetLife Investment Management’s Palvella Therapeutics PVLA Stock Holding History

MetLife Investment Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$531K	Hold	4,260	–	–	﹤0.01%	1732
2025 Q4	$446K	Hold	4,260	–	–	﹤0.01%	1850
2025 Q3	$267K	Hold	4,260	–	–	﹤0.01%	2148
2025 Q2	$96K	Buy	+4,260	New	+$100K	﹤0.01%	2564
2019 Q4	–	Sell	-307	Closed	-$83.8K	–	2333
2019 Q3	$83.8K	Buy	+307	New	+$119K	﹤0.01%	2319
2018 Q4	–	Sell	-258	Closed	-$116K	–	2598
2018 Q3	$116K	Hold	258	–	–	﹤0.01%	2338
2018 Q2	$105K	Hold	258	–	–	﹤0.01%	2160
2018 Q1	$141K	Buy	+258	New	+$160K	﹤0.01%	2075

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MetLife Investment Management's PVLA Position: Q1 2026 in Review

MetLife Investment Management held its Palvella Therapeutics (PVLA) position steady in Q1 2026 at 4,260 shares worth $531K. The position accounts for ﹤0.01% of the portfolio, ranked #1732.

MetLife Investment Management first reported a position in PVLA in Q1 2018 and has held it in 8 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

MetLife Investment Management held 4,260 shares of Palvella Therapeutics worth $531K as of Q1 2026.
MetLife Investment Management left its Palvella Therapeutics share count unchanged in Q1 2026.
Palvella Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1732 holding.
MetLife Investment Management first reported a position in Palvella Therapeutics in Q1 2018 and has held it in 8 quarters since.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.